Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aerpio Pharmaceuticals Inc    ARPO

AERPIO PHARMACEUTICALS INC

(ARPO)
My previous session
Most popular
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensus 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/15/2019 03/18/2019 03/19/2019 03/20/2019 03/21/2019 Date
4.25(c) 1.21(c) 1.12(c) 1.05(c) 1.08(c) Last
652 785 6 757 699 3 047 378 2 893 274 1 569 395 Volume
+2.91% -71.53% -7.44% -6.25% +2.86% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -38,9 M
Net income 2019 -38,3 M
Finance 2019 63,0 M
Yield 2019 -
Sales 2020 3,75 M
EBIT 2020 -40,1 M
Net income 2020 -39,4 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 0
Capi. / Sales2020 11,7x
Capitalization 43,8 M
More Financials
Company
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which... 
More about the company
Surperformance© ratings of Aerpio Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on AERPIO PHARMACEUTICALS INC
03/19AERPIO PHARMACEUTICALS : Announces Results From TIME-2b Study of AKB-9778 in Dia..
AQ
03/18AERPIO PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
03/18AERPIO PHARMACEUTICALS : Announces Results From TIME-2b Study of AKB-9778 in Dia..
BU
03/07AERPIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
03/05AERPIO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Fi..
AQ
03/05AERPIO PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2018 Financial Res..
BU
02/26AERPIO PHARMACEUTICALS : to Announce Fourth Quarter and Full Year 2018 Financial..
BU
01/17AERPIO PHARMACEUTICALS : Announces Completion of Patient Dosing in TIME-2b Study..
BU
01/07AERPIO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
2018AERPIO PHARMACEUTICALS : to Present at the Stifel 2018 Healthcare Conference
BU
More news
Sector news : Bio Therapeutic Drugs
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Bio Therapeutic Drugs
Chart AERPIO PHARMACEUTICALS INC
Duration : Period :
Aerpio Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AERPIO PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 6,00 $
Spread / Average Target 456%
Managers
NameTitle
Stephen J. Hoffman Chief Executive Officer & Director
Joseph H. Gardner President & Director
Muneer A. Satter Chairman
Michael W. Rogers Chief Financial & Accounting Officer
Kevin Patrick Peters Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
AERPIO PHARMACEUTICALS INC-36.47%44
GILEAD SCIENCES3.79%82 398
VERTEX PHARMACEUTICALS10.17%46 013
REGENERON PHARMACEUTICALS7.80%43 537
GENMAB8.52%10 912
SAREPTA THERAPEUTICS INC16.00%9 125